Reevaluating the Accelerated Approval Process for Oncology Drugs
Authors:
Open Access
- 30 May 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (11) , 2804-2809
Abstract
For a new therapy to qualify for the accelerated approval pathway, it must treat a serious disease for which there is “unmet medical need”—defined as providing a therapy where none exists or providing a therapy that may be potentially superior to existing therapy. The increasing number of available therapies, coupled with the lack of accepted endpoints considered “reasonably likely to predict clinical benefit” and the lack of clarity early in development about circumstances in which a new product will qualify for accelerated approval, is pushing developers to pursue accelerated approval in heavily pretreated patients to fulfill an unmet need. To optimize the accelerated approval pathway, we propose here a reevaluation of what constitutes “unmet medical need” and “available therapy” in oncology. We also discuss ways for new endpoints to become qualified for use in supporting accelerated approval, and propose a structured process for pursuing accelerated approval. Clin Cancer Res; 19(11); 2804–9. ©2013 AACR.Keywords
This publication has 19 references indexed in Scilit:
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Accelerated approval dust begins to settleNature Reviews Drug Discovery, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Minimal Residual Disease in Acute Lymphoblastic LeukemiaHematology-American Society Hematology Education Program, 2010
- Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?Journal of Clinical Oncology, 2009
- Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphomaLeukemia & Lymphoma, 2009
- Validation of novel imaging methodologies for use as cancer clinical trial end-pointsEuropean Journal of Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug DevelopmentClinical Cancer Research, 2005
- Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor MarkersJNCI: Journal of the National Cancer Institute, 1996